Article

Schwind eye-tech-solutions premieres new excimer laser

Kleinosheim, Germany-Schwind eye-tech-solutions premiered its new excimer laser (Amaris) at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Kleinosheim, Germany-Schwind eye-tech-solutions premiered its new excimer laser (Amaris) at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Among its features, the laser offers a pulse frequency of 500 Hz, two automatically adapted fluence levels for ablation control, and what the company says is the fastest eye tracker on the market-with a response time of less than 3 milliseconds-compensating every movement of the eye up to the fifth dimension. In addition, with online pachymetry, the laser continuously measures corneal thickness during the treatment, allowing the surgeon to decide at any time how best to proceed with a refractive correction.

One-month results of the first international multicenter LASIK study with the laser are encouraging in regard to visual acuity (VA), predictability, and variance, according to the company. The study involved 389 myopic eyes in patients aged 18 to 60 years. Some of the patients also had astigmatism.

The preoperative spherical equivalent (SE) ranged from –0.50 to –8.25 D, and astigmatism was treated up to –5.00 D. Postoperatively, an average SE of –0.16 D with a standard deviation of 0.25 D was observed. In 74% of all treated eyes, the planned refractive result was achieved within a minimum deviation of ±0.25 D after 1 month. Ninety-three percent of eyes were in the range of ±0.50 D, and 100% of eyes were within ±1.00 D. High postoperative stability was observed after 1 week.

Also after 1 month, postoperative uncorrected VA of 20/20 or better was achieved in more than 92% of treated patients. No single patient eye had a VA of less than 20/32. In 99%, a UCVA of 20/25 or better was achieved, and VA of 20/16 or better was achieved in more than 32% of study participants.

No trend toward overcorrection or undercorrection was detected after 1 month. All results were obtained without the use of individual nomograms.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.